{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
NeuroBo Pharmaceuticals, Inc.
Is NeuroBo Pharmaceuticals, Inc. technically bullish or bearish?
As of June 13, 2025, NeuroBo Pharmaceuticals, Inc. shows a mildly bearish trend due to mixed signals from indicators like MACD, Bollinger Bands, and moving averages, suggesting a cautious outlook.
Who are in the management team of NeuroBo Pharmaceuticals, Inc.?
As of March 2022, the management team of NeuroBo Pharmaceuticals, Inc. includes Chairman Douglas Swirsky, CEO Dr. Jeong Gu Kang, and COO Akash Bakshi, along with independent directors Jason Groves, Jeong Gyun Oh, and Michael Salsbury.
What does NeuroBo Pharmaceuticals, Inc. do?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative disorders, with a market cap of $13.56 million and a recent net profit of -$4 million. The company is classified as a micro-cap and has no dividend yield.
How big is NeuroBo Pharmaceuticals, Inc.?
As of Jun 18, NeuroBo Pharmaceuticals, Inc. has a market capitalization of 13.56 million and reported net sales of 0.00 million with a net profit of -24.54 million over the last four quarters. Shareholder's funds are 7.93 million, and total assets amount to 16.26 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
